Clinical trials: Expanded-spectrum Beta-lactamase Producing ESBL
Urinary Infection, Digestive Infection
Deescalating Carbapenems in Hospital Setting
The study aims to evaluate a deescalating therapeutic strategy (switch the carbapenem to another beta-lactam for which the isolated pathogen is susceptible) in patients with well-defined ESBL-PE infections (usual sites of…
- Conditions
- Urinary Infection, Digestive Infection, Biliary Infection, Expanded-spectrum Beta-lactamase Producing ESBL
- Trial name
- CARBEPARGNE (NCT02265445)
- Testing
- Deescalation therapy, Maintaining carbapenem therapy
- Volunteers
- 6 people
- Sponsor
- Assistance Publique - Hôpitaux de Paris